Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Arafat Ali Farooqui, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Saad Farooqi, MD, Maimoona Khan, MBBS, Aqsa Ashraf, MD, Ahmad Anjum, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5546.

https://doi.org/10.1182/blood-2019-121999

Published: 2019

Journal Articles

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Arafat Ali Farooqui, MD, Ahmad Anjum, MD, Muhammad Saad Farooqi, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Aqsa Ashraf, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5548.

https://doi.org/10.1182/blood-2019-122395

Published: 2019

Journal Articles

Real-World Utilization and Safety of Daratumumab Rapid Infusion Administered in a Community Setting: A Retrospective Observational Study

Lucio Gordon, MD, Melody Chang, RPh, MBA, Marie-Hélène Lafeuille, MA, Hela Romdhani, PhD, Faud Paramasivam, Xinmei Zhu, PhD, Sriya Gunawardena, Eric M Maiese, PhD

Blood (2019) 134 (Supplement_1): 5575.

https://doi.org/10.1182/blood-2019-128515

Published: 2019

Journal Articles

A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors

Hanna A. Knaus, MD, Hubert Hackl, Amanda Blackford, Sofia Berglund, Raul Montiel-Esparza, Joshua F Zeidner, MD, Ivana Gojo, MD, Leo Luznik, MD

Blood (2019) 134 (Supplement_1): 2711.

https://doi.org/10.1182/blood-2019-128742

Published: 2019

Journal Articles

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Virginia Campos Silvestrini, BSc, MSc, Eduardo M Rego, MD PhD, Vitor Marcel Faca, PhD, João Agostinho Machado-Neto, PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 2689.

https://doi.org/10.1182/blood-2019-132129

Published: 2019

Journal Articles

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Micah Denay McCumber, BS, MS, Aaron Mark Wendelboe, PhD MS, Janis Campbell, PhD GISP, Kai Ding, PhD, Michele G Beckman, MPH, Nimia L Reyes, MD MPH, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3463.

https://doi.org/10.1182/blood-2019-130604

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

Journal Articles

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Enrique M. Ocio, MD, Paula Rodriguez Otero, MD, Sara Bringhen, MD, Stefania Oliva, Axel Nogai, MD, Michel Attal, MD PhD, Philippe Moreau, Dheepak Kanagavel, Thomas F Fitzmaurice, PhD, Junlong Wu, Joaquin Martinez Lopez, MD PhD

Blood (2018) 132 (Supplement 1): 595.

https://doi.org/10.1182/blood-2018-99-111244

Published: 2018

Journal Articles

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Frederic Picou, PhD, Jean-Claude Chomel, PharmD PhD, Marie Christine Bene, PharmD, Marc G. Berger, MD PhD, Thierry Fest, Valerie Ugo, MD PhD, Eric Lippert, MD PhD, Marion Socco-Luca, Martine Delain, MD, Marie-Helene Estienne, PharmD, Olivier Herault, MD PhD

Blood (2018) 132 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2018-99-118297

Published: 2018

Journal Articles

Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT

Francesco Manfredi, MD, Maddalena Noviello, PhD, Eliana Ruggiero, PhD, Tommaso Perini, MD, Giacomo Oliveira, PhD, Filippo Cortesi, PhD, Pantaleo De Simone, MD, Cristina Toffalori, Valentina Gambacorta, MSc, Raffaella Greco, MD, Jacopo Peccatori, Monica Casucci, PhD, Giulia Casorati, PhD, Paolo Dellabona, MD PhD, Nicoletta Cieri, MD PhD, Attilio Bondanza, MD, Luca Vago, MD PhD, Fabio Ciceri, MD, Chiara Bonini, MD

Blood (2018) 132 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2018-99-118104

Published: 2018

Journal Articles

Generation of Memory Stem T Cells Specific for Tumor Antigens and Resistant to Inhibitory Signals By Genome Editing

Beatrice Claudia Cianciotti, Alessia Potenza, Valentina Vavassori, Zulma Magnani, Luigi Naldini, MD PhD, Fabio Ciceri, MD, Pietro Genovese, PhD, Eliana Ruggiero, PhD, Chiara Bonini, MD

Blood (2018) 132 (Supplement 1): 2202.

https://doi.org/10.1182/blood-2018-99-118201

Published: 2018

Journal Articles

The Pharmacological IGF1R-IRS1/2 Inhibitor NT157 Presents Multiple Anti-Neoplastic Effects in Myeloproliferative Neoplasms

Bruna Alves Fenerich, BSc, João Agostinho Machado-Neto, BSc, Ana Paula Nunes Rodrigues Alves, MSc, Paula De Melo Campos, MD PhD, Jaqueline Cristina Fernandes, BSc, MSc, Juan Luiz Coelho-Silva, BSc, MSc, Renata Scopim Ribeiro, BSc, MSc, Fernanda B da Silva, BSc and MSc, Priscila Santos Scheucher, PhD, Lorena Lobo Figueiredo-Pontes, MD PhD, Eduardo Magalhães Rego, MDPhD, Fabiola Traina, MD PhD

Blood (2017) 130 (Supplement 1): 1253.

https://doi.org/10.1182/blood.V130.Suppl_1.1253.1253

Published: 2017

Journal Articles

Early and Profound Exhausted Phenotype of Central Memory and Memory Stem T Cells in the Bone Marrow of AML Patients Characterizes and Predicts Relapse after Allo-HSCT

Maddalena Noviello, PhD, Francesco Manfredi, MD, Tommaso Perini, MD, Oliveira Giacomo, PhD, Filippo Cortesi, PhD, Pantaleo De Simone, MD, Cristina Toffalori, PhD, Valentina Gambacorta, MSc, Attilio Bondanza, MD, Raffaella Greco, MD, Jacopo Peccatori, MD, Giulia Casorati, PhD, Paolo Dellabona, MD PhD, Nicoletta Cieri, MD PhD, Luca Vago, MD PhD, Fabio Ciceri, MD, Chiara Bonini, MD

Blood (2017) 130 (Supplement 1): 4491.

https://doi.org/10.1182/blood.V130.Suppl_1.4491.4491

Published: 2017

Journal Articles

Increased Incidence of Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia Among Adults of Hispanic Ethnicity: A Population Based Study

Ashley M. Perry, BS, Evan C. Chen, MD, Marla M. Jalbut, MD, Lillian Werner, MS, Gabriela S. Hobbs, MD, Philip C. Amrein, MD, Amir T. Fathi, MD MD BS, Andrew M. Brunner, MD

Blood (2017) 130 (Supplement 1): 2570.

https://doi.org/10.1182/blood.V130.Suppl_1.2570.2570

Published: 2017

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Naoki Takezako, MD PhD, Kensuke Ohta, MD PhD, Hiroshi Handa, MD PhDChief Division, Mitsuo Hori, MD PhD, Gen Kinoshita, Suresh Shelat, Masafumi Miyoshi, Kohmei Kubo

Blood (2017) 130 (Supplement 1): 434.

https://doi.org/10.1182/blood.V130.Suppl_1.434.434

Published: 2017

Journal Articles

Concordant Underexpression of Fanconi Anemia/BRCA1 Pathway Proteins in a Major Proportion of Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Ulrich Germing, M. D., Ron-Patrick Cadeddu, Stefan Braunstein, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2016) 128 (22): 4311.

https://doi.org/10.1182/blood.V128.22.4311.4311

Published: 2016

Journal Articles

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

John F. Seymour, MD, Rena Buckstein, MD, Valeria Santini, MD, Hartmut Döhner, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Ching-Yuan Kuo, MD, Dina Ben-Yehuda, MD, Joan Bargay, MD, Stephen Songer, PharmD, Jerry Weaver, PhD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 2818.

https://doi.org/10.1182/blood.V128.22.2818.2818

Published: 2016

NARROW

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Real-World Utilization and Safety of Daratumumab Rapid Infusion Administered in a Community Setting: A Retrospective Observational Study

A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT

Generation of Memory Stem T Cells Specific for Tumor Antigens and Resistant to Inhibitory Signals By Genome Editing

The Pharmacological IGF1R-IRS1/2 Inhibitor NT157 Presents Multiple Anti-Neoplastic Effects in Myeloproliferative Neoplasms

Early and Profound Exhausted Phenotype of Central Memory and Memory Stem T Cells in the Bone Marrow of AML Patients Characterizes and Predicts Relapse after Allo-HSCT

Increased Incidence of Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia Among Adults of Hispanic Ethnicity: A Population Based Study

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Concordant Underexpression of Fanconi Anemia/BRCA1 Pathway Proteins in a Major Proportion of Myelodysplastic Syndromes

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only